Alpha-1 antitrypsin (Omni Bio Pharmaceutical)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAlpha-1 antitrypsin (Omni Bio Pharmaceutical)
Drug Alias NamePlasma-derived alpha 1 antitrypsin (Omni Bio Pharmaceutical)α1-抗胰蛋白酶 - Omni Bio Pharmaceuticalα1-胰蛋白酶抑制药 - Omni Bio Pharmaceuticalα-1 antitrypsin (Omni Bio Pharmaceutical)p-AAT
ClassificationBiologics > Blood components
Mechanisms of ActionPancreatic triacylglycerol lipase inhibitorsTrypsin inhibitors
TargetsPancreatic triacylglycerol lipaseTrypsin
Therapy Area/IndicationsGraft vs Host DiseaseDiabetes Mellitus, Type 1Myocardial Infarction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Colorado At Denver
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOmni Bio Pharmaceutical IncUniversity Of Colorado At DenverColorado State University Foundation +[4] 
Active IndicationsN/A
Inactive IndicationsGraft vs Host DiseaseDiabetes Mellitus, Type 1Myocardial Infarction

Other Information

ATC CodeN/A
Related LinksN/A